Inventor
HUDSON RYAN
US51 patents
⚠️ This page may combine multiple inventors who share the name “HUDSON RYAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
THERAVANCE BIOPHARMA R&D IP LLC
17 patentsUS10028960B2Jul 24, 2018
Pyrimidine compounds as JAK kinase inhibitors
THERAVANCE BIOPHARMA R&D IP LLC18 citations93
US9725470B2Aug 8, 2017
Substituted naphthyridines as JAK kinase inhibitors
THERAVANCE BIOPHARMA R&D IP LLC27 citations93
US10308646B2Jun 4, 2019
Pyrimidine compound as JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC11 citations92
US11420965B2Aug 23, 2022
Pyrimidine compound as JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC3 citations84
US10774080B2Sep 15, 2020
Pyrimidine compound as JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC5 citations84
US10562894B2Feb 18, 2020
Pyrimidine compound as JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC7 citations84
US11780852B2Oct 10, 2023
Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
THERAVANCE BIOPHARMA R&D IP LLC3 citations83
US10947254B2Mar 16, 2021
Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
THERAVANCE BIOPHARMA R&D IP LLC3 citations83
US11110095B2Sep 7, 2021
Pyrimidine compounds as JAK kinase inhibitors
THERAVANCE BIOPHARMA R&D IP LLC3 citations72
US10961267B2Mar 30, 2021
Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
THERAVANCE BIOPHARMA R&D IP LLC3 citations70
US12358931B2Jul 15, 2025
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC0 citations62
US12172994B2Dec 24, 2024
Pyrimidine compound as JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC0 citations62
US11814377B2Nov 14, 2023
Pyrimidine compound as JAK kinase inhibitor
THERAVANCE BIOPHARMA R&D IP LLC0 citations62
US11608354B2Mar 21, 2023
Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
THERAVANCE BIOPHARMA R&D IP LLC0 citations60
US9873696B2Jan 23, 2018
Neprilysin inhibitors
THERAVANCE BIOPHARMA R&D IP LLC0 citations52
US10435428B2Oct 8, 2019
Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
THERAVANCE BIOPHARMA R&D IP LLC0 citations49
US10745405B2Aug 18, 2020
Glucuronide prodrugs of Janus kinase inhibitors
THERAVANCE BIOPHARMA R&D IP LLC0 citations36
UNITY BIOTECHNOLOGY INC
7 patentsUS10981892B2Apr 20, 2021
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC2 citations73
US10717722B2Jul 21, 2020
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC2 citations73
US10519197B1Dec 31, 2019
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC3 citations73
US12221433B2Feb 11, 2025
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC0 citations62
US10689416B2Jun 23, 2020
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC0 citations52
US10745429B2Aug 18, 2020
Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC0 citations41
US10703745B2Jul 7, 2020
Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
UNITY BIOTECHNOLOGY INC0 citations41
THERAVANCE INC
5 patentsUS8372984B2Feb 12, 2013
Dual-acting oxazole antihypertensive agents
THERAVANCE INC16 citations93
US7956054B2Jun 7, 2011
Dual-acting pyrazole antihypertensive agents
THERAVANCE INC21 citations92
US7834041B2Nov 16, 2010
Dual-acting antihypertensive agents
THERAVANCE INC29 citations92
US7777077B2Aug 17, 2010
Dual-acting antihypertensive agents
THERAVANCE INC34 citations91
US8350027B2Jan 8, 2013
Dual-acting pyrazole antihypertensive agents
THERAVANCE INC0 citations52
CHOI SEOK-KI
5 patentsUS8143298B2Mar 27, 2012
Dual-acting antihypertensive agents
CHOI SEOK-KI1 citations62
US8106082B2Jan 31, 2012
Dual-acting antihypertensive agents
CHOI SEOK-KI3 citations62
US8735625B2May 27, 2014
Dual-acting antihypertensive agents
CHOI SEOK-KI0 citations51
US8394846B2Mar 12, 2013
Dual-acting antihypertensive agents
CHOI SEOK-KI0 citations51
US8236839B2Aug 7, 2012
Dual-acting antihypertensive agents
CHOI SEOK-KI0 citations51
SMITH CAMERON
3 patentsCORVUS PHARMACEUTICALS INC
3 patentsUS10870652B2Dec 22, 2020
Compounds and methods for modulating bruton's tyrosine kinase
CORVUS PHARMACEUTICALS INC2 citations73
US11897874B2Feb 13, 2024
Compounds and methods for modulating Interleukin-2-inducible T-cell kinase
CORVUS PHARMACEUTICALS INC0 citations62
US11008314B2May 18, 2021
Compounds and methods for modulating interleukin-2-inducible t-cell kinase
CORVUS PHARMACEUTICALS INC1 citations62
BLAIR BROOKE
2 patentsNEUMORA THERAPEUTICS INC
2 patentsFATHEREE PAUL R
2 patentsALLEGRETTI PAUL
2 patentsTHERAVANCE BIOPHARMA R & D IP LLC
1 patentANGEL PHARMACEUTICAL CO LTD
1 patentShowing the top 50 of 51 patents by PatentIndex Score.